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Despite remission rates of approximately 85% for children diagnosed with acute myeloid leukemia (AML),
greater than 40% will die from relapsed disease. Patients with poor-risk molecular/cytogenetics and/or
inadequate response to up-front therapy are typically considered high-risk (HR) and historically have poor
outcomes with chemotherapy alone. We investigated whether allogeneic hematopoietic cell transplantation
(allo-HCT) with best available donor in ﬁrst remission (CR1) would abrogate the poor outcomes associated
with HR AML in children and young adults treated with chemotherapy. We reviewed the outcomes of 50
consecutive children and young adults (ages 0 to 30 years) with AML who received a myeloablative allo-HCT
between 2001 and 2010. Thirty-six patients (72%) were HR, deﬁned as having FLT3-ITD mutations, 11q23 MLL
rearrangements, chromosome 5 or 7 abnormalities, induction failure, and/or having persistent disease. The
majority of patients received cyclophosphamide and total body irradiation conditioning, and graft-versus-
host-disease (GVHD) prophylaxis was cyclosporine based. Transplantation outcomes for HR patients were
compared to standard-risk patients, with no signiﬁcant differences observed in overall survival (72% versus
78%, P ¼ .72), leukemia-free survival (69% versus 79%, P ¼ .62), relapse (11% versus 7%, P ¼ .71), or treatment-
related mortality (17% versus 14%, P ¼ .89). Children and young adults with HR-AML have comparable
outcomes to standard-risk patients following allo-HCT in CR1.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION report no beneﬁt of HCT compared with chemotherapy
Children diagnosed with acute myeloid leukemia (AML)
have not had the same success as children treated for acute
lymphoblastic leukemia [1,2]. Despite the majority of chil-
dren with AML achieving complete remission following
intensive induction therapy, 40% will die from either disease
relapse or treatment-related toxicities [3]. Allogeneic hema-
topoietic cell transplantation (allo-HCT) using a matched
sibling donor (MSD) has remained the standard of care for
children with AML in ﬁrst complete remission (CR1), partic-
ularly for patients who lack favorable characteristics (eg,
t[8;21] translocation; inv[16] or t[16;16] translocation) [4]. In
contrast, most cooperative group studies have suggested that
those patients with high-risk features (eg, FLT3/ITD, mono-
somy 5 or 7, del 5q) [4,5] or poor response to up-front
chemotherapy (eg, induction failure or having persistent
disease) [6,7] receive transplantation with best available
donor since these children have less than a 40% chance of
survival when treated with chemotherapy alone [8,9].
Despite the use of allo-HCT for high-risk (HR) AML patients in
ﬁrst remission, outcomes remain poor with several studiesdgments on page 1024.
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13.04.001alone, questioning the rationale of HCT for HR patients
[4,10-12]. Whether HCT outcomes for these patients have
improved in the current era remains in question.
Here we report outcomes for children, adolescents, and
young adults with HR and standard-risk (SR) AML who
received an allo-HCT in CR1 at our institution between 2001
and 2010. We hypothesized that in the current era of allo-
HCT, there would be no signiﬁcant difference in survival for
SR and HR patients. This observation would, therefore,
support the practice of recommending allo-HCT in CR1 with
best available donor for children, adolescents, and young
adults with HR AML.PATIENTS AND METHODS
Study Design and Patient Characteristics
Patient characteristics are shown in Table 1. Fifty patients, ages 0 to
30 years, diagnosed with HR and SR AML underwentmyeloablative allo-HCT
in CR1 at the University of Minnesota between 2001 and 2010. Patients with
Down syndrome, acute promyelocytic leukemia, relapsed AML, treatment-
related AML, as well as those who received a nonmyeloablative allo-HCT
or a prior allo-HCT were excluded from this analysis. All patients and/or
their parents or guardians signed consent to participate on institutional
review boardeapproved transplantation protocols, and outcomes were
subsequently reviewed retrospectively. Thirty-six patients (72%) were
classiﬁed as HR and 14 (28%) as SR. For the purpose of this analysis, HR AML
was deﬁned as patients who had either monosomy 5 (n ¼ 0) or 7 (n ¼ 3),
deletion 5q (n¼ 2), FLT3/ITDwith a high allelic ratio (>.4) (n¼ 6),11q23MLL
gene rearrangement (n ¼ 8) (excluding the favorable t[1;11][q21;q23]; MLL
AF1q), biphenotypic lineage leukemia (n¼ 5), induction failure (>15% blasts
before starting the second induction course) (n ¼ 10), or morphological
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Table 1
Patient Characteristics
Factor HR AML SR AML P Value
n 36 14
Age, yr .80
Median (range) 15.1 (.5-30.2) 14.3 (1.9-25.7)
Gender .02
Male 18 (50) 12 (85.7)
Donor source <.001
Bone marrow 7 (19.4) 11 (78.6)
Related BM donor 4 (57) 7 (64)
Related PBSC 3 (43) 4 (36)
Umbilical cord blood 29 (80.6) 3* (21.4)
Single 8 (28) 0
Double 21 (72) 3* (100)
Recipient CMV .30
Positive 26 (72.2) 8 (57.1)
Negative 10 (27.8) 6 (42.9)
Conditioning <.001
CY/Flu/TBI 24 (66.7) 3 (21.4)
CY/Flu/TBI/ATG 1 (2.8) 0
CY/TBI 6 (16.7) 5 (35.7)
Busulfan-containing 5 (13.8) 6 (42.9)
GVHD Prophylaxis
CSA/MMF 27 (75.0) 3 (21.4)
CSA/MTX 6 (16.7) 10 (71.4) <.001
CSA/PD/ATG 3 (8.3) 0
GVHD .13
Acute II-IV
Yes 13 (36.1) 2 (14.3)
No 23 (63.9) 12 (85.7)
Acute III-IV .67
Yes 4 (11.1) 1 (7.1)
No 32 (88.9) 13 (92.9)
Chronic .21
Yes 8 (22.2) 1 (7.1)
No 28 (77.8) 13 (92.9)
HR indicates high risk; AML, acute myeloid leukemia; SR, standard risk;
PBSC, peripheral blood stem cell; CY, cyclophosphamide; Flu, ﬂudarabine;
TBI, total body irradiation; ATG, anti-thymocyte globulin; CSA, cyclosporine;
MMF, mycophenolate mofetil; MTX, methotrexate; PD, prednisone.
Data are presented as n (%) unless otherwise indicated.
* Related umbilical cord blood.
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patients classiﬁed as SR, based on their absence of HR features, had either
a normal karyotype (n ¼ 6); translocation involving t(8;21), (n ¼ 4), trisomy
8 (n ¼ 3), trisomy 4 (n ¼ 1); and/or the presence of monosomy 18 (n ¼ 1).
These 14 SR patients were allocated to allo-HCT in CR1 based on the avail-
ability of an MSD and, therefore, were not treated with chemotherapy alone.
The median age at time of allo-HCT for the entire cohort was 14.9
(range, .5 to 30.2) years with a median follow-up of 4.86 years (range, 1.10
to 10.19). Eighteen (50%) patients with HR AML and 12 (85.7%) with SR AML
were male (P¼ .02). The median time from diagnosis to allo-HCT was 129.5
days (range, 67 to 277) for HR patients and 131 days (range, 83 to 219) for
SR patients (P ¼ .91). The majority of both HR (69%, n ¼ 25) and SR (64%,
n ¼ 9) patients received their allo-HCT between 2005 and 2010, compared
with those receiving allo-CHT from 2001 to 2004 (30.6%, n ¼ 11 and 35.7%,
n ¼ 5, respectively, P ¼ .73). The majority of both HR (72.2%) and SR (57.1%)
patients were seropositive for cytomegalovirus (CMV) before trans-
plantation (P ¼ .30).
Donor Selection and Conditioning Regimens
Stem cell sources included HLA-MSD bone marrow, matched related
peripheral blood stem cell (PBSC), and matched related and unrelated
umbilical cord blood (UCB). Patients with HR AML received UCB (80.6%, n ¼
29), PBSC (8.3%, n ¼ 3), and matched related donor (MRD) (11.1%, n ¼ 4),
whereas all the SR patients received MSD grafts comprised of bone marrow
(50%, n ¼ 7), PBSC (28.6%, n ¼ 4), and UCB (21.4%, n ¼ 3) (P < .001). The
signiﬁcant discrepancy in the number of UCB recipients observed between
the 2 groups is likely the result of many of the SR patients being excluded for
allo-HCT if they only had a matched related UCB donor and our own insti-
tutional priority for cord blood for unrelated allo-HCT recipients.
Myeloablative conditioning, consisting of cyclophosphamide (120
mg/kg)þ/ﬂudarabine (75mg/m2) and totalbody irradiation (1320 cGy),was
used in 78% of patients (n ¼ 39). The remaining 22% (n ¼ 11) receivedmyeloablative doses of busulfan/cyclophosphamide or busulfan/
melphalan þ/ ﬂudarabine. Graft-versus-host-disease (GVHD) prophylaxis
comprised cyclosporine-based combinations in all patients.
Statistical Methods
Five outcomes were studied: overall survival (OS), leukemia-free
survival (LFS), transplantation-related mortality (TRM), GVHD, and relapse.
The Kaplan-Meier method was used to estimate OS and LFS, whereas
cumulative incidence was used to estimate TRM, GVHD, and relapse [14,15].
Cox multiple regression models were conducted for OS and LFS. Competing
risk regression was employed for TRM, GVHD, and risk of relapse. HR versus
SR was the primary factor considered for each endpoint in both univariate
and multivariate regression. Other covariates used in the models included
gender, CMV status, bone marrow versus UCB, HLA matching (in the case of
double cord transplantation, the matching of the engrafting cord was used),
and year of transplantation. The backward method was used to determine
the ﬁnal model, with a P value of.05 considered signiﬁcant in all statistical
tests. The study had sufﬁcient power to identify a difference in trans-
plantation outcomes based on disease risk group. Statistical analysis was
performed with Statistical Analysis System statistical software version 9.2
(SAS Institute, Cary, NC).
RESULTS
Neutrophil Engraftment
Engraftment by day 42 post-HCT (deﬁned as 3 consecu-
tive days with an absolute neutrophil count >500/l)
occurred in 90% (n ¼ 32) of HR patients and 100% (n ¼ 14) of
SR patients (P ¼ .08). The median time to neutrophil
engraftment for HR patients was 22 days (range, 2 to 38)
compared with 21 days (14 to 26) for SR patients (P ¼ .44).
Twenty-seven of the 32 patients who received UCB grafts
engrafted by day 42 post-HCT, compared with all 18 recipi-
ents of BM and PBSC grafts (88%; 95% conﬁdence interval [CI],
73% to 96% versus 100%; P < .01). In multivariate analysis,
there were no signiﬁcant differences identiﬁed between the
probability of engraftment among the SR and HR patients
(hazard ratio, 1.74; 95% CI, .80 to 3.75; P ¼ .16).
Overall Survival and Leukemia-Free Survival
Comparing survival outcomes between HR and SR groups,
there was no signiﬁcant difference in OS (72%; 95% CI, 54% to
84% versus 78%; 95% CI, 46% to 92%; P ¼ .72) or LFS (69%; 95%
CI, 51% to 82% versus 79%; 95% CI, 47% to 93%; P ¼ .62) at
5 years in univariate analysis (Figure 1A,B). This ﬁnding was
conﬁrmed in a multivariate analysis that demonstrated
similar OS (hazard ratio, .64; 95% CI, .17 to 2.36; P ¼ .50) and
LFS (hazard ratio, .56; 95% CI, .15 to 2.04; P¼ .38) between the
2 groups (Table 2).
Treatment-Related Mortality and GVHD
In univariate analysis, the cumulative incidence of TRM at
1 year was similar between HR and SR patients (17%; 95% CI,
5% to 29% versus 14%; 95% CI, 0 to 32%; P ¼ .89, Figure 2A).
This similarity persisted in multivariate analysis where no
signiﬁcant differences were found (hazard ratio, .50; 95% CI,
.04 to 5.46; P ¼ .57, Table 2). Similarly, univariate analysis
showed no signiﬁcant differences in TRM between the 2 graft
sources (marrow versus UCB), presence of GVHD, or recipient
CMV seropositivity before HCT. Causes of TRM for the HR
patients included organ failure (n ¼ 1), infection (n ¼ 2),
GVHD (n ¼ 2), and graft failure (n ¼ 2), compared with
infection (n ¼ 2) for the SR patients.
Disease risk status (HR versus SR) was not a signiﬁcant
factor in the development of grades II to IV acute GVHD (36%;
95% CI, 20% to 52% versus 14%; 95% CI, 0 to 32%; P ¼ .13),
grades III or IV acute GVHD (11%; 95% CI, 1% to 21% versus 7%;
95% CI, 0 to 20%; P¼ .67), or chronic GVHD (22%; 95% CI, 9% to
36% versus 0%; 95% CI, 0 to 0%; P ¼ .06). In the multivariate
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Figure 2. Treatment-related mortality (TRM) and relapse for high-risk (HR)
and standard-risk (SR) patients. (A) Cumulative incidence of TRM for HR
versus SR patients (17% versus 14%, P ¼ .89). (B) Cumulative incidence of
relapse for HR versus SR patients (11% versus 7%, P ¼ .71).
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Figure 1. Overall survival (OS) and leukemia-free survival (LFS) for high-risk
(HR) and standard-risk (SR) patients. (A) OS of HR versus OR for SR patients
(72% versus 78%, P ¼ .72). (B) Cumulative incidence of LFS for HR versus SR
patients (69% versus 79%, P ¼ .62).
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opment of acute GVHD grades II to IV (hazard ratio, .35; 95%
CI, .08 to 1.58; P¼ .17) or grades III to IV (hazard ratio,1.1; 95%
CI, .14 to 8.75; P ¼ .93) between HR and SR patients. Chronic
GVHD was signiﬁcantly different between the 2 risk groups
in multivariate analysis as only HR patients developed
chronic GVHD (hazard ratio, 0; P < .01), a likely result of the
graft source discrepancies between these 2 groups.
Relapse
Rates of leukemia relapse were low in both groups of
patients in this study. In univariate analysis, there was no
signiﬁcant difference in relapse at 5 years between HR and
SR patients (11%; 95% CI, 1% to 21% versus 7%; 95% CI, 0 to
20%; P ¼ .71, Figure 2B), which continued in the multivariateTable 2
Multivariate Analysis Standard Risk versus High-Risk Acute Myeloid
Leukemia
Factor Relative Risk
(95% Conﬁdence Interval)
P value
Overall survival .64 (.17-2.36) .50
Leukemia-free survival .56 (.15-2.04) .38
Transplantation-related mortality .50 (.04-5.46) .57
Relapse .79 (.08-8.07) .84
Engraftment 1.71 (.85-3.46) .13
Acute GVHD (grade II-IV) .35 (.08-1.58) .17
Acute GVHD (grade III-IV) 1.10 (.14-8.75) .93
Chronic GVHD 0 (0-0) <.01model (hazard ratio, .79; 95% CI, .08 to 8.07; P¼ .84). Patients
who received a UCB allo-HCT with 4/6 HLA mismatch alleles
(n ¼ 11) reported no relapses, compared with patients
matched at 5/6 or 6/6 HLA alleles (P < .01). As well, there
were no relapses reported in patients who experienced
grades II to IV acute GVHD (n ¼ 15) compared with patients
who did not (P < .01).
DISCUSSION
In this single institution retrospective analysis of 50
pediatric and young adult patients with AML who received
an allo-HCT in CR1 from 2001 to 2010, we found no signiﬁ-
cant difference in survival or relapse between those with or
without high-risk disease. As previous studies in pediatric
AML have typically included transplantation data from older
time periods [4,16-19], when rates of TRM were found to be
greater and supportive care measures (including antifungal
therapy) less advanced, we investigated whether outcomes
for patients with HR AML would now be comparable to SR
AML patients.
It has been well documented that children with HR AML
who are treated with chemotherapy alone have higher rates
of treatment failure (relapse) and inferior survival compared
with those with SR disease [6,8,9,20]. Creutzig et al. reported
the long-term outcomes of the Berlin-Frankfurt-Muenster
(BFM) AML pediatric trials spanning from 1978 to 1998
[21]. In the earlier studies (AML-BFM 78 and AML-BFM 83),
SR and HR patients were treated with chemotherapy alone
without any recommendation for allo-HCT and reported
M.J. Burke et al. / Biol Blood Marrow Transplant 19 (2013) 1021e102510245-year event-free survivals (EFS) of 38  4% and 47  4%,
respectively. In AML-BFM 87 and AML-BFM 93, HR patients
who had an available matched related donor were allocated
to allo-HCT in CR1 (n ¼ 39) and reported similar EFS at
5 years of 64  3% compared with the HR patients who were
treated with chemotherapy alone 62  3% (n ¼ 317).
Whether allo-HCT can improve survival in patients with
HR AML is debateable. Most of the pediatric AML trans-
plantation literature reporting outcomes in HR patients have
included earlier periods and typically have not found
a beneﬁt to HCT [4,18-21]; as a result, data are limited on HCT
outcomes for pediatric HR AML in the current era. For
instance, the BFM group reported results of AML-BFM 98
(study period, 1998 to 2004), which allocated HR patients
with an available MSD to allo-HCT in CR1 and those without
an MSD to receive chemotherapy. The only HR group that
appeared to beneﬁt from allo-HCT were those with MLL
rearrangements, where HCT provided signiﬁcantly improved
outcomes compared with chemotherapy alone (5-year OS,
94  6% (n ¼ 18) versus 52  7% (n ¼ 49); P ¼ .01). The
outcomes of the other HR subgroups did not show differ-
ences between MSD allo-HCT and chemotherapy alone,
questioning the role of HCT for patients with HR disease.
More recently, Koh et al. reported their experience using allo-
HCT for 29 children with either HR or advanced AML [22].
These data included a 10-year period between 1998 and
2008 and reported improved 3-year OS and EFS of 77% (95%
CI, 65% to 99%) and 70% (95% CI, 57% to 93%), respectively, and
particularly low TRM (7%; 95% CI, 0% to 44%).
Several reports have demonstrated inferior outcomes for
acute leukemia patients who undergo allo-HCT in second
complete remission (CR2), compared with patients in CR1
[23-27]. Gassas et al. reported a comparison of children with
AML who underwent allo-HCT in CR1 (n ¼ 47) versus CR2
(n ¼ 23), with the CR2 patients having inferior survival
(3-year OS, 51  11% versus 74  7%; P ¼ .05) and much
greater TRM (38  11% versus 11  5%; P ¼ .01) compared
with patients who underwent transplantation in CR1 [26].
Thus, postponing allo-HCT based on the unavailability of an
MSD, particularly in patients with HR disease who are at
greater risk of treatment failure, may not be the most
prudent approach. This becomes particularly relevant in the
current era, when HCT outcomes for acute leukemia have
improved. These improvements have been largely from the
use of high-resolution HLA-typing and enhanced supportive
care (including improved antifungal agents), which has
resulted in similar outcomes regardless of donor source [28-
33], as well as the ability to identify minimal residual disease
in patients before HCT, which reportedly inﬂuences post-HCT
survival [34-36]. The Children’s Oncology Group is currently
exploring the concept of taking childrenwith HR AML to allo-
HCT with best available donor in ﬁrst remission in a large
prospective Phase III clinical trial (AAML1031). The results of
this study will be critical in determining whether allo-HCT
remains the best treatment today for children and young
adults with HR AML.
In summary, we report similar outcomes for children and
young adults with AML when undergoing transplantation in
ﬁrst remission, regardless of their risk status (HR or SR).
Based on the overall advancements in HLA-typing,
improvements in supportive care therapies, and the ability
to identify minimal residual disease in patients before HCT,
outcomes for pediatric patients with HR AML are achieving
new heights. With a >70% OS predicted for children with HR
AML who receive best available donor allo-HCT, which hasbeen reported not only by our own group but by others as
well [22], HCT in CR1 should remain the standard of care for
these patients. As new discoveries and advances occur in
chemotherapy, the continued role that allo-HCT will play in
the consolidative setting for patients with AML will need to
be addressed. Because this was a single-institution retro-
spective study with a relatively small cohort of pediatric and
young adult patients, further studies in both children and
adults should be pursued to verify our ﬁndings of similar
outcomes in HR and SR AML patients after allo-HCT in CR1.
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